BACKGROUND: Despite the high prevalence of hepatitis C virus (HCV) among persons living with HIV (PWH), the prevalence of HCV screening, treatment, and sustained virologic response (SVR) is unknown. This study aims to characterize the continuum of HCV screening and treatment among PWH in HIV care. SETTING: Adult patients enrolled at 12 sites of the HIV Research Network located in 3 regions of the United States were included. METHODS: We examined the prevalence of HCV screening, HCV coinfection, direct-acting antiretroviral (DAA) treatment, and SVR-12 between 2014 and 2015. Multivariate logistic regression was performed to identify characteristics associated with outcomes, adjusted for site. RESULTS: Among 29,071 PWH (age 18-87, 74.8% male, 44.4% black), 77.9% were screened for HCV antibodies; 94.6% of those screened had a confirmatory HCV RNA viral load test. Among those tested, 61.1% were determined to have chronic HCV. We estimate that only 23.4% of those eligible for DAA were prescribed DAA, and only 17.8% of those eligible evidenced initiating DAA treatment. Those who initiated treatment achieved SVR-12 at a rate of 95.2%. Blacks and people who inject drugs (PWID) were more likely to be screened for HCV than whites or those with heterosexual risk. Persons older than 40 years, whites, Hispanics, and PWID [adjusted odds ratio (AOR) 8.70 (7.74 to 9.78)] were more likely to be coinfected than their counterparts. When examining treatment with DAA, persons older than 50 years, on antiretroviral therapy [AOR 2.27 (1.11 to 4.64)], with HIV-1 RNA <400 [AOR 2.67 (1.71 to 4.18)], and those with higher Fib-4 scores were more likely to be treated with DAA. CONCLUSIONS: Although rates of screening for HCV among PWH are high, screening remains far from comprehensive. Rates of SVR were high, consistent with previously published literature. Additional programs to improve screening and make treatment more widely available will help reduce the impact of HCV morbidity among PWH.
BACKGROUND: Despite the high prevalence of hepatitis C virus (HCV) among persons living with HIV (PWH), the prevalence of HCV screening, treatment, and sustained virologic response (SVR) is unknown. This study aims to characterize the continuum of HCV screening and treatment among PWH in HIV care. SETTING: Adult patients enrolled at 12 sites of the HIV Research Network located in 3 regions of the United States were included. METHODS: We examined the prevalence of HCV screening, HCV coinfection, direct-acting antiretroviral (DAA) treatment, and SVR-12 between 2014 and 2015. Multivariate logistic regression was performed to identify characteristics associated with outcomes, adjusted for site. RESULTS: Among 29,071 PWH (age 18-87, 74.8% male, 44.4% black), 77.9% were screened for HCV antibodies; 94.6% of those screened had a confirmatory HCV RNA viral load test. Among those tested, 61.1% were determined to have chronic HCV. We estimate that only 23.4% of those eligible for DAA were prescribed DAA, and only 17.8% of those eligible evidenced initiating DAA treatment. Those who initiated treatment achieved SVR-12 at a rate of 95.2%. Blacks and people who inject drugs (PWID) were more likely to be screened for HCV than whites or those with heterosexual risk. Persons older than 40 years, whites, Hispanics, and PWID [adjusted odds ratio (AOR) 8.70 (7.74 to 9.78)] were more likely to be coinfected than their counterparts. When examining treatment with DAA, persons older than 50 years, on antiretroviral therapy [AOR 2.27 (1.11 to 4.64)], with HIV-1 RNA <400 [AOR 2.67 (1.71 to 4.18)], and those with higher Fib-4 scores were more likely to be treated with DAA. CONCLUSIONS: Although rates of screening for HCV among PWH are high, screening remains far from comprehensive. Rates of SVR were high, consistent with previously published literature. Additional programs to improve screening and make treatment more widely available will help reduce the impact of HCV morbidity among PWH.
Authors: Mark H Kuniholm; Terry Leach; Joseph Lunievicz; Noemí Olivo; Kathryn Anastos; Yvette Vazquez; Mark Brennan-Ing; Stephen E Karpiak; Oladipo Alao; Denis Nash; Jerome Ernst Journal: AIDS Patient Care STDS Date: 2015-12 Impact factor: 5.078
Authors: Eric M Yoshida; Mark S Sulkowski; Edward J Gane; Robert W Herring; Vlad Ratziu; Xiao Ding; Jing Wang; Shu-Min Chuang; Julie Ma; John McNally; Luisa M Stamm; Diana M Brainard; William T Symonds; John G McHutchison; Kimberly L Beavers; Ira M Jacobson; K Rajender Reddy; Eric Lawitz Journal: Hepatology Date: 2014-11-24 Impact factor: 17.425
Authors: Berkeley N Limketkai; Shruti H Mehta; Catherine G Sutcliffe; Yvonne M Higgins; Michael S Torbenson; Sherilyn C Brinkley; Richard D Moore; David L Thomas; Mark S Sulkowski Journal: JAMA Date: 2012-07-25 Impact factor: 56.272
Authors: Gregory J Dore; Frederick Altice; Alain H Litwin; Olav Dalgard; Edward J Gane; Oren Shibolet; Anne Luetkemeyer; Ronald Nahass; Cheng-Yuan Peng; Brian Conway; Jason Grebely; Anita Y M Howe; Isaias N Gendrano; Erluo Chen; Hsueh-Cheng Huang; Frank J Dutko; David C Nickle; Bach-Yen Nguyen; Janice Wahl; Eliav Barr; Michael N Robertson; Heather L Platt Journal: Ann Intern Med Date: 2016-08-09 Impact factor: 25.391
Authors: Judith A Aberg; Joel E Gallant; Khalil G Ghanem; Patricia Emmanuel; Barry S Zingman; Michael A Horberg Journal: Clin Infect Dis Date: 2014-01 Impact factor: 9.079
Authors: Christine U Oramasionwu; Joshua C Toliver; Terence L Johnson; Heather N Moore; Christopher R Frei Journal: BMC Infect Dis Date: 2014-10-10 Impact factor: 3.090
Authors: Oluwaseun Falade-Nwulia; Risha Irvin; Alana Merkow; Mark Sulkowski; Alexander Niculescu; Yngvild Olsen; Kenneth Stoller; David L Thomas; Carl Latkin; Shruti H Mehta Journal: J Subst Abuse Treat Date: 2019-01-30
Authors: Jun Li; Carl Armon; Frank J Palella; Ellen Tedaldi; Richard M Novak; Jack Fuhrer; Gina Simoncini; Kimberly Carlson; Kate Buchacz Journal: Open Forum Infect Dis Date: 2021-04-17 Impact factor: 3.835
Authors: Oluwaseun Falade-Nwulia; Paul Sacamano; Sean D McCormick; Cui Yang; Greg Kirk; David Thomas; Mark Sulkowski; Carl Latkin; Shruti H Mehta Journal: Int J Drug Policy Date: 2020-03-02
Authors: Oluwaseun Falade-Nwulia; Rachel E Gicquelais; Jacquie Astemborski; Sean D McCormick; Greg Kirk; Mark Sulkowski; David L Thomas; Shruti H Mehta Journal: Liver Int Date: 2020-10 Impact factor: 8.754